ArticleAntimicrobial agents and chemotherapy2014
Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.
Article in Antimicrobial agents and chemotherapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Efficacy of Inhalational Ciprofloxacin (Apulmiq) in an NHP Model of Q Fever.Antibiotics (Basel, Switzerland) · 2026Article
- Inhaled Ciprofloxacin as an Alternative Treatment for Infection withAntibiotics (Basel, Switzerland) · 2026Article
- Inhaled liposomal ciprofloxacin protects against lethal tularemia in the common marmoset.Antimicrobial agents and chemotherapy · 2026Article
- Development of a System to Deliver Inhalational Antibiotics to Marmosets.Antibiotics (Basel, Switzerland) · 2025Article
- Non-vaccinal prophylaxis of tularemia.Frontiers in microbiology · 2024Review
- A macrophage-targeted platform for extending drug dosing with polymer prodrugs for pulmonary infection prophylaxis.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- Efficacy of Levofloxacin Loaded Nonionic Surfactant Vesicles (Niosomes) in a Model ofAdvances in pharmacological and pharmaceutical sciences · 2020Article
- Article
- Common Host Responses in Murine Aerosol Models of Infection Caused by Highly Virulent Gram-Negative Bacteria from the Genera Burkholderia, Francisella and Yersinia.Pathogens (Basel, Switzerland) · 2019Article
- Nanoparticle Formulation of Moxifloxacin and Intramuscular Route of Delivery Improve Antibiotic Pharmacokinetics and Treatment of Pneumonic Tularemia in a Mouse Model.ACS infectious diseases · 2019Article
- Macrophage-targeted drugamers with enzyme-cleavable linkers deliver high intracellular drug dosing and sustained drug pharmacokinetics against alveolar pulmonary infections.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Polymer-augmented liposomes enhancing antibiotic delivery against intracellular infections.Biomaterials science · 2018Article
- Inhaled Liposomal Ciprofloxacin Protects against a Lethal Infection in a Murine Model of Pneumonic Plague.Frontiers in microbiology · 2017Article
- Tuning Ciprofloxacin Release Profiles from Liposomally Encapsulated Nanocrystalline Drug.Pharmaceutical research · 2016Article
- Nanoaerosols reduce required effective dose of liposomal levofloxacin against pulmonary murine Francisella tularensis subsp. novicida infection.Journal of nanobiotechnology · 2016Article
- Development of Liposomal Ciprofloxacin to Treat Lung Infections.Pharmaceutics · 2016Review
- Aerosol Performance and Stability of Liposomes Containing Ciprofloxacin Nanocrystals.Journal of aerosol medicine and pulmonary drug delivery · 2015Article
- Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead.Advanced drug delivery reviews · 2015Review
- Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever.Antimicrobial agents and chemotherapy · 2014Article
- The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.Frontiers in cellular and infection microbiology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Liposome-encapsulated ciprofloxacin for inhalation (CFI) was investigated as a putative postexposure therapeutic for two strains of Francisella tularensis. The efficacies of oral ciprofloxacin and intranasally instilled CFI could not be distinguished in a mouse model of infection with the F. tularensis live vaccine strain (LVS), where a single dose of either formulation offered full protection against a lethal challenge. However, mouse studies with the more virulent Schu S4 strain of F. tularensis demonstrated that a higher level of protection against a lethal aerosol infection is provided by CFI than by oral ciprofloxacin. In addition, using this infection model, it was possible to discriminate the efficacy of intranasally instilled CFI from that of aerosolized CFI, with aerosolized CFI providing full protection after just a single dose. The improved efficacy of CFI compared to oral ciprofloxacin is likely due to the high sustained concentrations of ciprofloxacin in the lung. In summary, CFI may be a promising therapy, perhaps enabling the prophylactic regimen to be shortened, for use in the event of a deliberate release of F. tularensis. The prophylactic efficacy of CFI against other biological warfare (BW) threat agents also warrants investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.